Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07537413 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia

Study acronym: DC-CAP
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from University of Maryland, Baltimore

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified
    • Enrollment increased: 430 → 900 participants
    • Study sites: 2 to 4
    • Secondary endpoints: 11 to 9
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Trial Details
NCT Number NCT07537413
Lead Sponsor University of Maryland, Baltimore
Conditions
(from sponsor)		 Community Acquired Pneumonia (CAP)
Related terms Community-Acquired Pneumonia
Enrollment 900 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov